MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

MDM2 is a key negative regulator of the tumor suppressor p53, however, the prognostic significance of MDM2 overexpression in diffuse large B-cell lymphoma (DLBCL) has not been defined convincingly. In a p53 genetically–defined large cohort of de novo DLBCL patients treated with rituximab, cyclophosp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Xu-Monette, Zijun Y., Møller, Michael B., Tzankov, Alexander, Montes-Moreno, Santiago, Hu, Wenwei, Manyam, Ganiraju C., Kristensen, Louise, Fan, Lei, Visco, Carlo, Dybkær, Karen, Chiu, April, Tam, Wayne, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W. L., van Krieken, J. Han, Huang, Qin, Huh, Jooryung, Ai, Weiyun, Ponzoni, Maurilio, Ferreri, Andrés J. M., Wu, Lin, Zhao, Xiaoying, Bueso-Ramos, Carlos E., Wang, Sa A., Go, Ronald S., Li, Yong, Winter, Jane N., Piris, Miguel A., Medeiros, L. Jeffrey, Young, Ken H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2013
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3952598/
https://ncbi.nlm.nih.gov/pubmed/23982177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-12-473702
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars